Literature DB >> 18057246

Cooperative effect of the attenuation determinants derived from poliovirus sabin 1 strain is essential for attenuation of enterovirus 71 in the NOD/SCID mouse infection model.

Minetaro Arita1, Yasushi Ami, Takaji Wakita, Hiroyuki Shimizu.   

Abstract

Enterovirus 71 (EV71) is a causative agent of hand, foot, and mouth disease and is also associated with serious neurological disorders. An attenuated EV71 strain [EV71(S1-3')] has been established in the cynomolgus monkey infection model; this strain contains the attenuation determinants derived from the type 1 poliovirus vaccine strain, Sabin 1 [PV1(Sabin)], in the 5' nontranslated region (NTR), 3D polymerase, and 3' NTR. In this study, we analyzed the effect of the attenuation determinants of PV1(Sabin) on EV71 infection in a NOD/SCID mouse infection model. We isolated a mouse-adapted EV71 strain [EV71(NOD/SCID)] that causes paralysis of the hind limbs in 3- to 4-week-old NOD/SCID mice by adaptation of the virulent EV71(Nagoya) strain in the brains of NOD/SCID mice. A single mutation at nucleotide 2876 that caused an amino acid change in capsid protein VP1 (change of the glycine at position 145 to glutamic acid) was essential for the mouse-adapted phenotype in NOD/SCID mice. Next, we introduced attenuation determinants derived from PV1(Sabin) along with the mouse adaptation mutation into the EV71(Nagoya) genome. In 4-week-old mice, the determinants in the 3D polymerase and 3' NTR, which are the major temperature-sensitive determinants, had a strong effect on attenuation. In contrast, the effect of individual determinants was weak in 3-week-old NOD/SCID mice, and all the determinants were required for substantial attenuation. These results suggest that a cooperative effect of the attenuation determinants of PV1(Sabin) is essential for attenuated neurovirulence of EV71.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18057246      PMCID: PMC2258712          DOI: 10.1128/JVI.01798-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  71 in total

1.  Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71.

Authors:  Cheng-Hsun Chiu; Chishih Chu; Chao-Che He; Tzou-Yien Lin
Journal:  Microbes Infect       Date:  2006-04-21       Impact factor: 2.700

2.  Interaction of poliovirus with its purified receptor and conformational alteration in the virion.

Authors:  M Arita; S Koike; J Aoki; H Horie; A Nomoto
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Temperature-sensitive mutants of enterovirus 71 show attenuation in cynomolgus monkeys.

Authors:  Minetaro Arita; Hiroyuki Shimizu; Noriyo Nagata; Yasushi Ami; Yuriko Suzaki; Tetsutaro Sata; Takuya Iwasaki; Tatsuo Miyamura
Journal:  J Gen Virol       Date:  2005-05       Impact factor: 3.891

4.  Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease.

Authors:  L Y Chang; T Y Lin; K H Hsu; Y C Huang; K L Lin; C Hsueh; S R Shih; H C Ning; M S Hwang; H S Wang; C Y Lee
Journal:  Lancet       Date:  1999-11-13       Impact factor: 79.321

5.  Pathogenicity of a poliomyelitis-like disease in monkeys infected orally with enterovirus 71: a model for human infection.

Authors:  I Hashimoto; A Hagiwara
Journal:  Neuropathol Appl Neurobiol       Date:  1982 Mar-Apr       Impact factor: 8.090

6.  Transgenic mice susceptible to poliovirus.

Authors:  S Koike; C Taya; T Kurata; S Abe; I Ise; H Yonekawa; A Nomoto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-02-01       Impact factor: 11.205

7.  Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model.

Authors:  A Martin; D Benichou; T Couderc; J M Hogle; C Wychowski; S Van der Werf; M Girard
Journal:  Virology       Date:  1991-02       Impact factor: 3.616

8.  Encapsidation studies of poliovirus subgenomic replicons.

Authors:  W Barclay; Q Li; G Hutchinson; D Moon; A Richardson; N Percy; J W Almond; D J Evans
Journal:  J Gen Virol       Date:  1998-07       Impact factor: 3.891

9.  Pathogenesis of enterovirus 71 brainstem encephalitis in pediatric patients: roles of cytokines and cellular immune activation in patients with pulmonary edema.

Authors:  Shih-Min Wang; Huan-Yao Lei; Kao-Jean Huang; Jing-Ming Wu; Jen-Ren Wang; Chun-Keung Yu; Ih-Jen Su; Ching-Chuan Liu
Journal:  J Infect Dis       Date:  2003-07-23       Impact factor: 5.226

10.  Immunity to avirulent enterovirus 71 and coxsackie A16 virus protects against enterovirus 71 infection in mice.

Authors:  Te-Chia Wu; Ya-Fang Wang; Yi-Ping Lee; Jen-Ren Wang; Ching-Chuan Liu; Shih-Min Wang; Huan-Yao Lei; Ih-Jen Su; Chun-Keung Yu
Journal:  J Virol       Date:  2007-07-11       Impact factor: 5.103

View more
  55 in total

1.  Forecasting the economic value of an Enterovirus 71 (EV71) vaccine.

Authors:  Bruce Y Lee; Angela R Wateska; Rachel R Bailey; Julie H Y Tai; Kristina M Bacon; Kenneth J Smith
Journal:  Vaccine       Date:  2010-10-16       Impact factor: 3.641

2.  Reemergence of enterovirus 71 in 2008 in taiwan: dynamics of genetic and antigenic evolution from 1998 to 2008.

Authors:  Sheng-Wen Huang; Yun-Wei Hsu; Derek J Smith; David Kiang; Huey-Pin Tsai; Kuei-Hsiang Lin; Shih-Min Wang; Ching-Chung Liu; Ih-Jen Su; Jen-Ren Wang
Journal:  J Clin Microbiol       Date:  2009-09-23       Impact factor: 5.948

3.  Development of a poliovirus neutralization test with poliovirus pseudovirus for measurement of neutralizing antibody titer in human serum.

Authors:  Minetaro Arita; Masae Iwai; Takaji Wakita; Hiroyuki Shimizu
Journal:  Clin Vaccine Immunol       Date:  2011-08-31

4.  Amino Acid Variation at VP1-145 of Enterovirus 71 Determines Attachment Receptor Usage and Neurovirulence in Human Scavenger Receptor B2 Transgenic Mice.

Authors:  Kyousuke Kobayashi; Yui Sudaka; Ayako Takashino; Ayumi Imura; Ken Fujii; Satoshi Koike
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

5.  VP1 Amino Acid Residue 145 of Enterovirus 71 Is a Key Residue for Its Receptor Attachment and Resistance to Neutralizing Antibody during Cynomolgus Monkey Infection.

Authors:  Ken Fujii; Yui Sudaka; Ayako Takashino; Kyousuke Kobayashi; Chikako Kataoka; Tadaki Suzuki; Naoko Iwata-Yoshikawa; Osamu Kotani; Yasushi Ami; Hiroyuki Shimizu; Noriyo Nagata; Katsumi Mizuta; Yoko Matsuzaki; Satoshi Koike
Journal:  J Virol       Date:  2018-07-17       Impact factor: 5.103

6.  Valosin-containing protein (VCP/p97) is required for poliovirus replication and is involved in cellular protein secretion pathway in poliovirus infection.

Authors:  Minetaro Arita; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2012-02-29       Impact factor: 5.103

7.  A Novel Murine Model Expressing a Chimeric mSCARB2/hSCARB2 Receptor Is Highly Susceptible to Oral Infection with Clinical Isolates of Enterovirus 71.

Authors:  Cheng-Hung Yang; Chung-Tiang Liang; Si-Tse Jiang; Kuan-Hsing Chen; Chun-Chiao Yang; Mei-Ling Cheng; Hung-Yao Ho
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

8.  The cross-reactivity of the enterovirus 71 to human brain tissue and identification of the cross-reactivity related fragments.

Authors:  Chun Shi Jia; Jiang Ning Liu; Wan Bo Li; Chun Mei Ma; Shu Zhu Lin; Yi Hao; Xue Zhong Gao; Xiao Lin Liu; Yan Feng Xu; Lian Feng Zhang; Chuan Qin
Journal:  Virol J       Date:  2010-02-22       Impact factor: 4.099

9.  Producing infectious enterovirus type 71 in a rapid strategy.

Authors:  Jian-Feng Han; Rui-Yuan Cao; Xue Tian; Man Yu; E-De Qin; Cheng-Feng Qin
Journal:  Virol J       Date:  2010-06-04       Impact factor: 4.099

10.  Development of a reverse transcription-loop-mediated isothermal amplification (RT-LAMP) system for a highly sensitive detection of enterovirus in the stool samples of acute flaccid paralysis cases.

Authors:  Minetaro Arita; Hua Ling; Dongmei Yan; Yorihiro Nishimura; Hiromu Yoshida; Takaji Wakita; Hiroyuki Shimizu
Journal:  BMC Infect Dis       Date:  2009-12-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.